Prognostic significance of the null genotype of glutathione S-transferase-T1 in patients with acute myeloid leukemia: increased early death after chemotherapy

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Leukemia

• Publication date

  2002-02-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/sj.leu.2402361PMID 11840286
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Glutathione S-transferase polymorphisms and outcome of chemotherapy in childhood acute myeloid leukemia.

  2001cited by this paper
• Glutathione S-transferase theta 1 gene deletion and risk of acute myeloid leukemia.

  2000cited by this paper
• Analysis of genetic polymorphism in NQO1, GST-M1, GST-T1, and CYP3A4 in 469 Japanese patients with therapy-related leukemia/ myelodysplastic syndrome and de novo acute myeloid leukemia.

  2000cited by this paper
• Glutathione S-transferase polymorphisms in children with myeloid leukemia: a Children's Cancer Group study.

  2000cited by this paper
• Substantially reduced risk of cancer of the aerodigestive tract in subjects with variant--463A of the myeloperoxidase gene.

  2000cited by this paper
• No beneficial effect from addition of etoposide to daunorubicin, cytarabine, and 6-mercaptopurine in individualized induction therapy of adult acute myeloid leukemia: the JALSG-AML92 study. Japan Adult Leukemia Study Group.

  1999cited by this paper
• Molecular diagnosis and clinical decisions in adult acute leukemia.

  1999cited by this paper
• Molecular diagnosis and clinical decisions in adult acute leukemia.

  1999cited by this paper
• The glutathione S-transferases: influence of polymorphism on cancer susceptibility.

  1999cited by this paper
• Acute myeloid leukemia.

  1999cited by this paper
• Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia.

  1999cited by this paper
• Has the prognosis of adult patients with acute myeloid leukemia improved over years? A single institution experience of 784 consecutive patients over a 16-year period

  1999cited by this paper
• Polymorphisms of N-acetyltransferases, glutathione S-transferases, microsomal epoxide hydrolase and sulfotransferases: influence on cancer susceptibility.

  1998cited by this paper
• Association of glutathione S-transferase GSTM1 and GSTT1 null genotypes with clinical outcome in epithelial ovarian cancer.

  1998cited by this paper
• Benzene exposure, glutathione S-transferase theta homozygous deletion, and sister chromatid exchanges.

  1998cited by this paper
• Molecular epidemiology of the human glutathione S-transferase genotypes GSTM1 and GSTT1 in cancer susceptibility.

  1997cited by this paper
• Higher frequency of glutathione S-transferase deletions in black children with acute lymphoblastic leukemia.

  1997cited by this paper
• ATP-dependent transport of aflatoxin B1 and its glutathione conjugates by the product of the multidrug resistance protein (MRP) gene.

  1997cited by this paper
• Glutathione S transferase theta 1 gene defects in myelodysplastic syndromes and their correlation with karyotype and exposure to potential carcinogens

  1997cited by this paper
• Pharmacogenetics in cancer etiology and chemotherapy.

  1997cited by this paper
• Higher Frequency of Glutathione S-Transferase Deletions in Black Children With Acute Lymphoblastic Leukemia

  1997cited by this paper
• Internal tandem duplication of FLT3 associated with leukocytosis in acute promyelocytic leukemia

  1997cited by this paper
• Increased risk for myelodysplastic syndromes in individuals with glutathione transferase theta 1 (GSTT1) gene defect.

  1996cited by this paper
• Influence of erythrocyte glutathione S-transferase T1 on sister chromatid exchanges induced by diepoxybutane in cultured human lymphocytes.

  1996cited by this paper
• Randomized trials between behenoyl cytarabine and cytarabine in combination induction and consolidation therapy, and with or without ubenimex after maintenance/intensification therapy in adult acute myeloid leukemia. The Japan Leukemia Study Group.

  1996cited by this paper
• More on genetic predisposition

  1995cited by this paper
• Sister-chromatid exchanges, glutathione S-transferase theta deletion and cytogenetic sensitivity to diepoxybutane in lymphocytes from butadiene monomer production workers.

  1995cited by this paper
• The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance.

  1995cited by this paper
• Role of GSTT1and GSTM1genotypes in determining individual sensitivity to sister chromatid exchange induction by diepoxybutane in cultured human lymphocytes

  1995cited by this paper
• Role of GSTT1 and GSTM1 genotypes in determining individual sensitivity to sister chromatid exchange induction by diepoxybutane in cultured human lymphocytes.

  1995cited by this paper
• Gene deletion of glutathione S-transferase theta: correlation with induced genetic damage and potential role in endogenous mutagenesis.

  1995cited by this paper
• Human glutathione S-transferase theta (GSTT1): cDNA cloning and the characterization of a genetic polymorphism.

  1994cited by this paper
• Structure and function of glutathione S-transferases.

  1994cited by this paper
• Randomized study of individualized induction therapy with or without vincristine, and of maintenance-intensification therapy between 4 or 12 courses in adult acute myeloid leukemia. AML-87 Study of the Japan Adult Leukemia Study Group.

  1993cited by this paper
• Randomized study of individualized induction therapy with or without vincristine, and of maintenance—intensification therapy between 4 or 12 courses in adult acute myeloid leukemia. AML‐87 study of the Japan adult leukemia study group

  1993cited by this paper
• Overexpression of glutathione S-transferase and elevation of thiol pools in a multidrug-resistant human colon cancer cell line.

  1992cited by this paper
• Reduced topoisomerase II and elevated alpha class glutathione S-transferase expression in a multidrug resistant CHO cell line highly cross-resistant to mitomycin C.

  1992cited by this paper
• Denitrosation of 1,3-bis(2-chloroethyl)-1-nitrosourea by class mu glutathione transferases and its role in cellular resistance in rat brain tumor cells.

  1989cited by this paper
• Biological and molecular bases of mammary carcinogenesis.

  1987cited by this paper
• Biochemical genetics of glutathione-S-transferase in man.

  1981cited by this paper

• Assessing the genetic profile of cytochrome P450 and glutathione S-transferases of patients diagnosed with acute myeloid leukemia

  2025cites this paper
• Role of Germline Predisposition to Therapy-Related Myeloid Neoplasms

  2022cites this paper
• ELN 2017 classification significantly impacts the risk of early death in acute myeloid leukemia patients receiving intensive induction chemotherapy

  2022cites this paper
• Influence of polymorphisms in anthracyclines metabolism genes in the standard induction chemotherapy of acute myeloid leukemia

  2021cites this paper
• GSTM1 and GSTT1 copy number variants and the risk to Thai females of hepatocellular carcinoma.

  2019cites this paper
• 10.11 – Quinone Reductases☆

  2018cites this paper
• Pharmacogenomics and the treatment of acute myeloid leukemia.

  2016cites this paper
• Original Article The factors affecting early death after the initial therapy of acute myeloid leukemia

  2015cites this paper
• The factors affecting early death after the initial therapy of acute myeloid leukemia.

  2015cites this paper
• GSTT1 and GSTM1 polymorphisms predict treatment outcome for breast cancer: a systematic review and meta-analysis

  2015cites this paper
• GSTT1 and GSTM1 polymorphisms predict treatment outcome for acute myeloid leukemia: a systematic review and meta-analysis

  2014cites this paper
• Translational implications of somatic genomics in acute myeloid leukaemia.

  2014cites this paper
• A pilot pharmacogenomics study examining the influence of cytotoxic and metabolising genetic polymorphisms on chemotherapy toxicity and outcome in osteosarcoma

  2013influential citation
• PharmGKB summary: very important pharmacogene information for GSTT1

  2012cites this paper
• Chemotherapy and Mechanisms of Resistance in Breast Cancer

  2012cites this paper
• Two minor NQO1 and NQO2 alleles predict poor response of breast cancer patients to adjuvant doxorubicin and cyclophosphamide therapy

  2011cites this paper
• Interactions between Glucocorticoid Treatment and Cis-Regulatory Polymorphisms Contribute to Cellular Response Phenotypes

  2011cites this paper
• Pharmacogenetic and Pharmacogenomic Considerations in the Biology and Treatment of Childhood Leukemia

  2011cites this paper
• An integrated genomic approach to the assessment and treatment of acute myeloid leukemia.

  2011cites this paper
• 4.11 – Quinone Reductases

  2010cites this paper
• GSTT1, GSTM1, and GSTP1 polymorphisms and chemotherapy response in locally advanced breast cancer.

  2010cites this paper
• Glutathione S-transferase polymorphisms in osteosarcoma patients

  2010cites this paper
• Glutathione S‐transferase polymorphisms are associated with survival in anaplastic glioma patients

  2010cites this paper
• Acute myeloid leukemia.

  2010cites this paper
• Glutathione-S-transferase genotypes influence the risk of chemotherapy-related toxicities and prognosis in Korean patients with diffuse large B-cell lymphoma.

  2010cites this paper
• A deletion polymorphism in glutathione-S-transferase mu (GSTM1) and/or theta (GSTT1) is associated with an increased risk of toxicity after autologous blood and marrow transplantation.

  2010cites this paper
• Clinical significance of GSTM1 and GSTT1 polymorphisms in younger patients with acute myeloid leukemia of intermediate-risk cytogenetics.

  2009cites this paper
• Glutathione s-transferase polymorphisms in breast cancers of Thai patients.

  2009cites this paper
• Glutathione S-transferase M1 and T1 polymorphisms may predict adverse effects after therapy in children with medulloblastoma.

  2009cites this paper
• Meta-analysis study of glutathione-S-transferases (GSTM1, GSTP1, and GSTT1) gene polymorphisms and risk of acute myeloid leukemia

  2009cites this paper
• Pharmacogenomics in acute myeloid leukemia.

  2009cites this paper
• An overview of the relations between polymorphisms in drug metabolising enzymes and drug transporters and survival after cancer drug treatment.

  2009cites this paper
• Acute myeloid leukemia.

  2008cites this paper
• Glutathione S-transferases (GSTT1 and GSTM1) genes polymorphisms and the treatment response and prognosis in Chinese patients with de novo acute myeloid leukemia.

  2008cites this paper
• DNA Polymorphisms Affecting Chemosensitivity Toward Drugs

  2008cites this paper
• Pharmacogenetics and Pharmacokinetics in high-dose alkylating chemotherapy

  2008cites this paper
• Pharmacogenetics in Cancer Management: Scenario for Tailored Therapy

  2008cites this paper
• Genetic variants contributing to daunorubicin-induced cytotoxicity.

  2008cites this paper
• The use of glutathione transferase-knockout mice as pharmacological and toxicological models

  2007cites this paper
• Polymorphisms in genes encoding drug metabolizing enzymes and their influence on the outcome of children with neuroblastoma

  2007cites this paper
• The GST deletions and NQO1*2 polymorphism confers interindividual variability of response to treatment in patients with acute myeloid leukemia.

  2007cites this paper
• Ancestry and pharmacogenetics of antileukemic drug toxicity.

  2007cites this paper
• Pharmacogenomics of acute leukemia.

  2007cites this paper
• Expression of glutathione S-transferase T1 (GSTT1) in human brain tumours.

  2006cites this paper
• Pharmacogenomics of acute leukemia.

  2006cites this paper
• Potential application of GSTT1-null genotype in predicting toxicity associated to 5-fluouracil irinotecan and leucovorin regimen in advanced stage colorectal cancer patients.

  2006cites this paper
• Is tailored therapy feasible in oncology?

  2006cites this paper
• Glutathione S-transferase (GSTM1, GSTT1 and GSTA1) polymorphisms and outcomes after treatment for acute myeloid leukemia: pharmacogenetics in Southwest Oncology Group (SWOG) clinical trials

  2006cites this paper
• Nutrigenomics and Pharmacogenomics of Human Cancer: On the Road from Nutrigenetics and Pharmacogenetics

  2006cites this paper
• Genetic Polymorphisms and Risk Assessment for Cancer Chemoprevention

  2005cites this paper
• Pharmacogenetics for individualized cancer chemotherapy.

  2005cites this paper
• Predicting drug response and toxicity based on gene polymorphisms.

  2005cites this paper
• Common gene polymorphisms, cancer progression and prognosis.

  2004cites this paper
• [Therapy-related hematologic neoplasias after breast cancer. Epidemiologic, etiologic and cytogenetic aspects and new risk factors according to published data and own results].

  2004cites this paper
• Glutathione S-Transferase Polymorphisms and Survival in Primary Malignant Glioma

  2004cites this paper
• Pharmacogenetics of neoplastic diseases: new trends.

  2004cites this paper
• NAD(P)H:quinone oxidoreductase 1 (NQO1, DT-diaphorase), functions and pharmacogenetics.

  2004cites this paper
• Therapieinduzierte hämatologische Neoplasien nach Mammakarzinomen

  2004cites this paper
• Reanalysis of Cancer Drugs

  2004cites this paper
• Recent advances in the treatment and understanding of childhood acute lymphoblastic leukaemia.

  2003cites this paper
• Role of pharmacogenomics and pharmacodynamics in the treatment of acute lymphoblastic leukaemia.

  2002cites this paper
• Potential application of GSTT 1-null genotype in predicting toxicity associated to 5-fluouracil irinotecan and leucovorin regimen in advanced stage colorectal cancer patients

  year unknowncites this paper